Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Sell

Exponential Moving Average

Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Opthea Limited American Depositary Shares (OPT)

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/07/2011

Market Cap

382,909,792

Shares Outstanding

662,810,000

Weighted SO

82,850,861

Total Employees

N/A

Upcoming Earnings

09/12/2023

Beta

0.7990

Last Div

0.0000

Range

1.6-4.4

Chg

0.1850

Avg Vol

18395

Mkt Cap

382909792

Exch

NASDAQ

Country

AU

Phone

61 3 9826 0399

DCF Diff

1.5930

DCF

0.9873

Div Yield

0.0000

P/S

3268.7381

EV Multiple

-2.4603

P/FV

-4.4489

Div Yield %

0.0000

P/E

-1.2895

PEG

-0.2530

Payout

0.0000

Current Ratio

5.1039

Quick Ratio

5.1039

Cash Ratio

4.8195

DSO

18061.2294

DIO

0.0027

Op Cycle

18061.2320

DPO

84622.5120

CCC

-66561.2800

Gross Margin

-0.1674

Op Margin

-1412.0938

Pretax Margin

-1457.9721

Net Margin

-1381.7447

Eff Tax Rate

0.0523

ROA

-0.9721

ROE

6.1350

ROCE

-1.2353

NI/EBT

0.9477

EBT/EBIT

1.0325

EBIT/Rev

-1412.0938

Debt Ratio

1.0862

D/E

-3.8552

LT Debt/Cap

1.3505

Total Debt/Cap

1.3502

Int Coverage

-8.0743

CF/Debt

-0.6657

Equity Multi

-3.5491

Rec Turnover

0.0202

Pay Turnover

0.0043

Inv Turnover

136748.0000

FA Turnover

0.7577

Asset Turnover

0.0007

OCF/Share

-1.4969

FCF/Share

-1.4972

Cash/Share

1.9529

OCF/Sales

-1027.7743

FCF/OCF

1.0002

CF Coverage

-0.6657

ST Coverage

-1372.4785

CapEx Coverage

-6314.9477

Div&CapEx Cov

-6314.9477

P/BV

-4.4489

P/B

-4.4489

P/S

3268.7381

P/E

-1.2895

P/FCF

-3.1799

P/OCF

-1.7336

P/CF

-1.7336

PEG

-0.2530

P/S

3268.7381

EV Multiple

-2.4603

P/FV

-4.4489

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 04, 23:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF GlobeNewswire Inc. Mar 20, 01:45 Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call Benzinga Mar 20, 01:25 Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) GlobeNewswire Inc. Mar 20, 01:25 Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS) The Motley Fool Dec 29, 13:43 The Smartest Index ETF to Buy With $200 Right Now GlobeNewswire Inc. Jun 26, 01:35 Optiva Inc. Announces Results of Annual and Special Meeting GlobeNewswire Inc. Jun 19, 00:57 Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens GlobeNewswire Inc. Jun 13, 23:58 Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) GlobeNewswire Inc. Jun 12, 01:13 Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹) GlobeNewswire Inc. Jan 19, 10:13 Syntec Optics (Nasdaq: OPTX) Secures $4.8M Order for Medical Diagnostics Optics GlobeNewswire Inc. Jan 17, 13:34 Syntec Optics (Nasdaq: OPTX) to Display Innovations at Photonics West 2024 GlobeNewswire Inc. Jan 17, 08:44 Ocean Power Technologies Announces Progress on Shift to Commercialization and Expects to Achieve Profitability in Calendar Year 2025 GlobeNewswire Inc. Jan 11, 09:39 Syntec Optics (Nasdaq: OPTX) CEO Interviewed by New York Photonics Cluster GlobeNewswire Inc. Dec 27, 06:00 Opthea to Receive US$35M Commitment and Additional US$50M Funding GlobeNewswire Inc. Dec 20, 10:10 Syntec Optics Launches Innovative Thermal Clip-On Scope (Nasdaq: OPTX) GlobeNewswire Inc. Dec 19, 06:00 Opthea Receives A$8.8 million R&D Tax Incentive GlobeNewswire Inc. Dec 13, 16:45 Ocean Power Technologies, Inc. Announces Second Quarter Fiscal 2024 Results GlobeNewswire Inc. Dec 13, 16:45 Ocean Power Technologies, Inc. Announces Second Quarter Fiscal 2024 Results GlobeNewswire Inc. Dec 11, 10:38 Syntec Optics Expands Thin-Film Technology with Gold Coating Capabilities (Nasdaq: OPTX) Benzinga Dec 06, 14:45 Gold Moves Higher; Campbell Soup Earnings Top Expectations

Revenue Product Segmentation